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Introduction: B and T lymphocyte attenuator (BTLA) is an inhibitory receptor, whose primary role in CD4+ T cell is
thought to inhibit cytokine production. We explore BTLA expression on CD4+ T cells in healthy controls and septic
patients, and assess the correlation of BTLA expression on CD4+ T cells in the early stage of sepsis with the severity
and mortality of septic patients in the emergency department (ED).
Methods: 336 consecutive patients were included in this study. BTLA expression on CD4+ T cells was measured by
flow cytometry within 24h of ED admission.
Results: Our results showed that the percentage of BTLA+/CD4+ T cells was high expression in healthy volunteers
and it was statistically reduced in severe sepsis and septic shock compared with healthy controls(all P<0.01). The
area under the receiver operating characteristic (AUC) curves of BTLA expression on CD4+ T cells was slightly lower
than that of procalcitonin (PCT) and Mortality in Emergency Department Sepsis (MEDS) score. The percentage of
BTLA+/CD4+T cells was lower in non-survivors than in survivors (P<0.01), and similar results were obtained when
expressed as mean of fluorescence intensities (MFI) (P<0.01). Adjusted logistic regression analysis suggested that the
percentage of BTLA+/CD4+ T cells was associated with 28-day mortality in septic patients (odds ratio (OR) = 0.394).
Conclusion: Our study shows that the percentage of BTLA+/CD4+ T cells was high in healthy volunteers. Furthermore,
lower percentage of BTLA+/CD4+ T cells during the early stage of sepsis is associated with the severity and the
mortality of septic patients.Introduction
Sepsis, a systemic deleterious host inflammatory response
to infection, has a high mortality rate, especially in patients
with severe sepsis or septic shock [1]. Septic syndromes
involve overstimulated host response and ineffective
bacterial clearance [2, 3]. Immune system dysfunction
is widely accepted as the main pathophysiological
process in septic patients presenting as severely immu-
nocomprised and inefficient at clearing invasive micro-
bial pathogens [4, 5]. Negative co-inhibitory molecules,
including programmed death receptor-1 (PD-1), B and
T lymphocyte attenuator (BTLA) and other inhibitory* Correspondence: lcscyyy@163.com
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munosuppression [6].
BTLA is a recently characterized co-inhibitory mol-
ecule expressed on T cells, B cells, natural killer (NK)
cells, macrophages and dendritic cells [7, 8]. It plays a
role in regulating T cell function and attenuating pro-
survival signaling in CD4+ T cells [8, 9]. Studies have
shown that the level of expression of BTLA on circulat-
ing T lymphocytes is associated with nosocomial infec-
tions and mortality in sepsis [6, 10]. However, there are
conflicting reports on the level of BTLA expression on
CD4+ T cells in healthy controls and patients with sepsis
[6, 10]. Additionally, the relationship between the level
of BTLA expression on circulating CD4+ T lymphocytes
and the severity of sepsis has not been elucidated. Fur-
thermore, there have been no studies exploring whetherdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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associated with the mortality of patients with sepsis.
Given the above considerations, this prospective cohort
study was designed to explore the level of BTLA expres-
sion on circulating CD4+ T lymphocytes in healthy vol-
unteers and patients with sepsis. We also examined the
correlation between the level of BTLA expression on cir-
culating CD4+ T lymphocytes and the disease severity
and mortality of patients with sepsis.
Methods
Patients
Data were collected between May 2014 and January
2015 from patients admitted to the Emergency Depart-
ment (ED) of Beijing-Chao Hospital, an urban university
tertiary hospital with about 250,000 ED admissions an-
nually. Patients who were admitted to the ED on days 1
to 2 of the onset of the signs of systemic inflammatory
response syndrome (SIRS) were evaluated for possible
enrollment according to the inclusion and exclusion cri-
teria. Eligible patients were categorized into groups ac-
cording to the severity of disease (which included SIRS,
sepsis, severe sepsis, and septic shock), and blood sam-
ples were obtained within 24 h of enrollment.
SIRS, sepsis, severe sepsis, and septic shock were diag-
nosed according to the diagnostic criteria of the 2001
SCCM/ESICM/ACCP/ATS/SIS International sepsis defi-
nitions conference [11]. SIRS was defined with at least two
of the following criteria: (a) body temperature >38 °C
or <36 °C, (b) heart rate >90 beats per minute, (c) re-
spiratory rate >20 breaths per minute or arterial partial
pressure of carbon dioxide (PaCO2) <32 mmHg, (d)
white cell count >12,000/mm3 or <4,000/mm3, or the
presence of >10 % immature neutrophils. Sepsis was
defined by the presence of both infection and SIRS. Se-
vere sepsis was defined as sepsis-induced hypotension
or dysfunction. Septic shock was defined as sepsis-
induced hypotension persisting despite adequate fluid
resuscitation, and requiring vasopressor therapy. Ac-
cording to the criteria of the International Sepsis
Forum Consensus Conference on Definitions of Infec-
tion [12], the infection was defined on the basis of clinical
features, laboratory findings, and imaging tests. The cri-
teria for organ dysfunction were as follows: sepsis-induced
hypotension; lactate above normal upper limits; urine
output <0.5 ml/kg/h for more than 2 h despite ad-
equate fluid resuscitation, or creatinine >2.0 mg/dl
(176.8 μmol/L); acute lung injury with PaO2/inspired
oxygen fraction (FiO2) <250 mmHg in the absence of
pneumonia as infection source, or acute lung injury
with PaO2/FiO2 <200 mmHg in the presence of pneu-
monia as the infection source; bilirubin >2.0 mg/dl
(34.2 μmol/L); platelet count <100,000/mm3, or inter-
national normalized ratio >1.5. The exclusion criteriawere: (1) patient’s age <18 years; (2) patients with HIV
infection, viral hepatitis, and other pre-existing
hematological or immunological disease; (3) patients
who declined to consent, and (4) patients with signs of
SIRS occurring >3 days prior to admission, or patients
who were transferred from another hospital.
Clinical characteristics of patients, including demo-
graphic characteristics (age and gender); vital signs (heart
rate, respiratory rate, body temperature, and blood pres-
sure), and past medical history and correlative laboratory
examinations (white blood cell count (WBC), blood gas
analysis, blood biochemistry, imaging examination and
others) were collected upon enrollment. The mortality in
emergency department sepsis (MEDS) score was calcu-
lated using the related clinical and demographic data [13].
Fifty age-matched healthy controls with no history or clin-
ical disease were enrolled. This study was approved by the
Beijing Chao-yang Hospital Ethics Committee. Written
informed consents were obtained from the patients and
volunteers. Consents for patients who were unable to con-
sent were provided by first-degree relatives. According to
28-day survival, patients with sepsis, severe sepsis, and
septic shock were classified as surviving or non-surviving.
During the follow-up period, the enrolled patients who
died from any cause were classified as non-survivors.
Flow cytometry
Samples of peripheral blood were collected in ethylene-
diamine tetraaccetic acid (EDTA) anticoagulant tubes
and transported to the laboratory at 4 °C within 1 h. The
erythrocytes were lysed and cells were stained by re-
searcher who was blinded to the clinical data. According
to the manufacturer’s recommendations, monoclonal
antibodies and their isotype controls were used: phyco-
erythrin (PE)-labeled anti-BTLA (5 μl, clone J168-540;
BD Bioscience, San Jose, CA, USA), APC-H7 labeled
anti-CD3 (5 μl, clone SK7; BD Bioscience), fluorescein
isothiocyanate (FITC)-labeled anti-CD4 (clone OKT4;
eBioscience, San Diego, CA, USA) per 100 μl of whole
blood. Samples were run on the Gallios™ Flow Cyt-
ometer (Beckman Coulter, Inc.) and analyzed using
Gallios Software Version 1.0 (Beckman Coulter, Inc.).
Lymphocytes were gated by forward scatter (FSC) and
side scatter (SSC), and T cells subsets were further
identified by CD3+ and CD4+ staining (Fig. 1). At least
5,000 CD4+ T lymphocytes were analyzed from each
sample. Threshold was defined with the isotype control.
Results are expressed as percentage of BTLA+/CD4+ T
cells and its mean of fluorescence intensities (MFI).
Statistical analysis
The baseline characteristics are described as frequencies,
percentages, medians and inter-quartile ranges. Kruskal-
Wallis one-way analyses of variance was performed for
Fig. 1 Representative flow dot plots of lymphocyte gating strategy and the percentage of B and T lymphocyte attenuator (BTLA)+/CD4+ T cells in
five groups. All lymphocytes (gate A) were gated by forward scatter/side scatter (FSC/SSC), and then differentiating T cell subsets (gate D) based
on CD3+ staining in lymphocytes, and then CD4+ T cells (gate M) were further identified by CD4+ staining in T cells . The multiple dot plots of CD4 vs
BTLA are representative of the percentage of BTLA+/CD4+T cells in five groups (control, systemic inflammatory response syndrome (SIRS), sepsis, severe
sepsis, and septic shock). PE phycoerythrin, FITC fluorescein isothiocyanate, FSC INT LIN forward scatter integral linear, SS INT LIN side scatter integral linear
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using the Pearson chi squared (χ2) test for categorical
data and the Dunnett test (a post-hoc multiple compari-
sons test) for continuous variables. Receiver operating
characteristic (ROC) curves were established and the
area under the ROC curve (AUC) was determined to
evaluate the predictive qualities of BTLA expression on
CD4+ T cells. Differences in the AUC values were ana-
lyzed using the Z test formula. Binary logistic regres-
sion was used to analyze the variables associated with
28-day mortality. All statistical tests were two-tailed,
and P values of 0.05 or less were considered statisticallysignificant. All data were analyzed using SPSS 19.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of enrolled subjects
In total, 286 patients who met the eligibility criteria and
50 healthy controls were enrolled. There were no signifi-
cant differences in age, gender, or correlative diseases
among the patients in the five groups (control, SIRS,
sepsis, severe sepsis, and septic shock groups) (Table 1).
The baseline characteristics, diseases and associated in-
fections of all participants are also shown in Table 1.
Table 1 Baseline characteristics of the study population
Control SIRS Sepsis Severe sepsis Septic shock P value
Number 50 59 93 71 63
Age, years 68 (66−74) 70 (59−78) 71 (66−78) 73 (62−77) 74 (64−79) 0.34
Male, % 62.0 57.6 60.2 63.4 60.3 0.97
WBC, ×109/L 6.6 (5.6−7.6) 9.2 (8.1−11.6) 11.9 (9.6−14.2) 14.9 (10.9−17.7) 16.6 (13.5−19.6) <0.001
Lymphocytes, ×109/L 2.8 (2.4−3.1) 1.4 (1.0−1.7) 1.1 (0.9−1.7) 0.8(0.5−1.2) 0.6 (0.4−0.9) <0.001
PCT, g/ml 0.06 (0.05−0.1) 0.2 (0.05−0.3) 1.0 (0.2−2.1) 4.6 (0.9−8.1) 8.3 (1.8−22.3) <0.001
MEDS score 0 5 (3−7) 9 (6.5−11) 12 (9−16) 19 (16−23) <0.001
Percentage of BTLA+/CD4+T cells
90.3 (85.6−91.9) 91.3 (89.0−93.2) 88.4 (81.9−91.3) 86.5 (78.6−90.1) 79.5 (63.6−86.6) <0.001
MFI of BTLA on CD4+ T cells
7.2 (6.0−8.1) 10.2 (8.7−13.3) 8.7 (7.0−11.0) 7.6 (6.2−8.9) 6.5 (4.9−8.7) <0.001
Diagnosis (number)
Respiratory AECOPD (27) Pneumonia (58) Pneumonia (58) Pneumonia (58) 0.80
Asthma (14)
Abdominal Pancreatitis (8) IAI (17) IAI (13) IAI (11) 0.88
Urinary Pyelonephritis (4) Pyelonephritis (7) Pyelonephritis (4) 0.36
Cerebral Stroke (4) Meningitis (9) Meningitis (5) Meningitis (9) 0.44
Others DKA (6) Skin/soft tissue infection (5)
28-day mortality, number (%) 5 (8.5 %) 18 (19.5 %) 33 (46.5 %) 37 (58.7 %) <0.001
Data are shown as median and interquartile range (IQR) unless stated otherwise. WBC white blood cells, PCT procalcitonin, MEDS Mortality in Emergency
Department Sepsis, BTLA B and T lymphocyte attenuator, MFI mean of fluorescence intensities, AECOPD acute exacerbation of chronic obstructive pulmonary
disease, IAI intraabdominal infection, DKA diabetic ketoacidosis, ED Emergency Department, SIRS systemic inflammatory response syndrome
Shao et al. Critical Care  (2015) 19:308 Page 4 of 9The median values of WBC, absolute lymphocyte count
(ALC), procalcitonin (PCT), and MEDS score in each
group were significantly different. Notably, our results
showed that ALC was obviously decreased in patients with
sepsis. A summary of the values is shown in Table 1.
BTLA expression on CD4+T lymphocytes
The median levels of BTLA expression on CD4+T cells
in each group are presented in Table 1. The median
value of the percentage of BTLA+/CD4+T cells in
healthy volunteers was 90.2 % (85.5−91.9 %). Interestingly,
we observed that the percentage of BTLA+/CD4+T cells
was significantly reduced in patients with severe sepsis or
septic shock compared with healthy controls (all P <0.01).
This was also obviously reduced in patients with septic
shock compared with patients with severe sepsis (P <0.05),
However, there were no differences in the percentage of
BTLA+/CD4+T cells between patients with SIRS and
healthy volunteers or between patients with sepsis and
healthy controls (P >0.05). There was a stepwise reduction
in the percentage of BTLA+/CD4+T cells within 24 h of
ED admission in patients with SIRS compared with pa-
tients with sepsis, severe sepsis, or septic shock (P <0.01;
Figs. 1 and 2). We observed that the MFI of BTLA on
CD4+ T cells was significantly higher in patients with SIRS
or sepsis than in healthy controls (P <0.01), but there wasno statistically significant difference between the MFI of
BTLA on CD4+ T cells in patients with severe sepsis or
septic shock and healthy controls (all P >0.05).
The AUC of the percentage of BTLA+/CD4+ T cells
for predicting 28-day mortality was 0.693, which was not
statistically significantly different compared with the
MEDS score (0.743) or PCT (0.726) according to the Z
test (all P >0.05; Fig. 3). The ROC curve analysis showed
that the optimal threshold for predicting 28-day mor-
tality in patients was 82.25 % of BTLA+/CD4+ T cells
(sensitivity 53.4 %, specificity 72.7 %, positive predictive
value (PPV) 55.3 %, negative predictive value (NPV)
71.1 %). Similarly, the AUC of the MFI of BTLA ex-
pression on CD4+ T cells for predicting 28-day mortal-
ity was 0.653, which was slightly lower than that of the
MEDS score (0.743) or PCT (0.726) according to the Z
test (all P >0.05; Fig. 3). The best cutoff of the MFI of
BTLA expression on CD4+ T cells for predicting 28-
day mortality in patients was 7.54 (sensitivity 62.5 %,
specificity 64 %, PPV 52.4 %, NPV 73 %).
The percentage of BTLA+/CD4+T cells was lower in
non-survivors compared with survivors (P <0.01). Simi-
lar results were obtained when expressed as MFI of
BTLA on CD4+ T cells (P <0.01; Fig. 4).
In multivariate analysis, the logistic regression model
was adjusted for age, gender, WBC, ALC, PCT
Fig. 2 The percentage of B and T lymphocyte attenuator (BTLA)+/
CD4+ T cells in five groups. There was a stepwise reduction in the
percentage of BTLA+/CD4+T cells from patients with systemic
inflammatory response syndrome (SIRS) compared to patients with
sepsis, severe sepsis, or septic shock
Fig. 3 Receiver operating characteristic (ROC) curve for predicting
28-day mortality in patients with sepsis. Areas under the curve
(AUCs) for predicting 28-day mortality: procalcitonin (PCT) (blue
line) 0.726 (95 % CI: 0.647 to 0.785), mortality in emergency
department sepsis (MEDS) score (green line) 0.743 (95 % CI: 0.672
to 0.814), percentage of B and T lymphocyte attenuator (BTLA)+/
CD4+ T cells (black line) 0.693 (95 % CI: 0.613 to 0.773), mean of
fluorescence intensities (MFI) of BTLA on CD4+ T cells (purple line)
0.653 (95 % CI: 0.569 to 0.736)
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BTLA+/CD4+T cells , and MFI of BTLA on CD4+ T
cells, to determine the relationship of 28-day mortality
in patients with sepsis, severe sepsis and septic shock.
The model was determined by the method of ENTER (de-
fault with the menu system). After univariate analysis, the
MEDS score, PCT, ALC, the percentage of BTLA+/CD4
+T cells, and MFI of BTLA on CD4+ T cells were included
in the final model (P <0.05). Using multivariate logistic
regression analysis, the percentage of BTLA+/CD4+T cells
(odds ratio (OR) = 0.869, 95 % CI: 0.769 to 0.981,
P = 0.023) is associated with the 28-day mortality, but
MFI of BTLA on CD4+ T cells was not (OR = 0.900, 95 %
CI: 0.789 to 1.025, P = 0.113). The detailed results are
illustrated in Table 2.
Discussion
The major findings of this study are the unexpected
results. We showed that the percentage of BTLA+/CD4+
T cells was high in healthy volunteers. In the early stage
of sepsis, there was a stepwise reduction in the percent-
age of BTLA+/CD4+T cells in patients with SIRS com-
pared with patients with sepsis, severe sepsis, or septic
shock. The percentages of BTLA+/CD4+T cells were sig-
nificantly reduced in patients with severe sepsis or septic
shock compared with healthy controls. Therefore, in the
early stage of sepsis, the percentage of BTLA+/CD4+T
cells may contribute to the risk stratification for sepsis.
Additionally, the percentage of BTLA+/CD4+T cells was
lower in non-survivors than in survivors, and it was as-
sociated with 28-day mortality in patients with sepsis.
Our findings suggest that not only did the percentage of
BTLA+/CD4+T cells correlate with the severity of sepsis,
but also it was valuable for prognostic evaluation of sep-
sis. Therefore, the percentage of BTLA+/CD4+T cells
was a predictor of pejorative outcome in patients with
sepsis as well. The unexpected results were inconsistent
with previous studies.
Sepsis is a complicated immune response, and in general
it involves massive release of inflammatory mediators
during the early stage, followed by rapid development
of an immunosuppression state [4, 14]. Immunosup-
pression that develops late in the disease course of sep-
tic syndromes presents as inability to clear the initial
infection and a loss of the delayed hypersensitivity re-
sponse [14, 15]. Co-inhibitory molecules act as negative
regulators of TCR-mediated activation and cytokine re-
leases during immune responses. In the early stage of
sepsis, expression of inhibitory molecules is increased
to prevent the cytokine storm from inducing organ fail-
ures. However, during the immunosuppression stage,
high expression of inhibitory molecules may be detri-
mental through the subsequent induction of T cell
anergy or immune cell deactivation. BTLA was initially
Fig. 4 Box-plot representation of the percentage of B and T lymphocyte attenuator (BTLA)+/CD4+ T cells (A) and mean of fluorescence
intensities (MFI) of BTLA+ on CD4+ T cells (B) according to outcome. Data are shown as box plot with medians (lines inside boxes), 25th and 75th
quartiles (limits of boxes) and whiskers indicate the range. The median of the percentage of BTLA+/CD4+ T cells or its MFI were higher in survivors
(n = 139) than in non-survivors (n = 88)
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roles in CD4+ T cells were thought to be the inhibition
of cytokine production and maintenance of a state of
immune tolerance to self-antigens [16, 17]. However,
Hurchla and colleagues found a pro-survival role of
BTLA in an in vivo model of chronic allostimulation
[18]. A study by Shubin and colleagues showed that
increased BTLA+CD4+ lymphocytes were found in
patients who developed a subsequent infection, and
that BTLA may be a potential biomarker and mediator
of sepsis-induced immunosuppression [10]. The differ-
ences between our study and that of Shubin and col-
leagues are detailed below.
Our results showed that the percentage of BTLA+/CD4+T
cells in healthy volunteers was about 90 %, while Shubin
and colleagues found the percentage of BTLA+/CD4+T
cells in healthy controls to be about 50 %. The discrep-
ancy between our results and those of Shubin andTable 2 Independent factors predicting 28-day mortality in patients
Variable B SE Wald
Percentage of BTLA+/CD4+ T cells −0.141 0.062 5.145
MFI of BTLA on CD4+ T cells −0.106 0.067 2.508
MEDS 0.180 0.033 29.358
PCT 0.022 0.015 2.206
ALC 0.256 0.277 0.856
Constant −2.155 0.756 8.120
BTLA B and T lymphocyte attenuator, MFI mean of fluorescence intensities, MEDS m
lymphocyte countcolleagues may be due to the fact that their sample size
of healthy controls (n = 6) was relatively small. Con-
versely, the percentage of BTLA+/CD4+T cells in
healthy controls from the study by Zhang and col-
leagues was in agreement with ours [19]. There is an-
other hypothesis. BTLA gene polymorphisms were not
present at the same frequencies in the Chinese Han
and the Caucasian population, and the basal expression
of BTLA on CD4+ T cell may be different between vari-
ous lineages. For example, several minor alleles of
BTLA in the Caucasian lineage are major alleles in the
Han Beijing population [20]. Shubin and colleagues also
measured the percentage of BTLA+/CD4+T cells in
patients with SIRS or sepsis. Interestingly, they found
that patients with sepsis had a significantly increased
percentage of BLTA+CD4+ lymphocytes compared with
patients with SIRS. The discrepancies between our
findings and those of shubin and colleagues may be duewith sepsis, severe sepsis, and septic shock
P value Odds ratio 95 % CI for EXP (B)
Lower limit Lower limit
0.023 0.869 0.769 0.981
0.113 0.900 0.789 1.025
<0.001 1.197 1.121 1.277
0.137 1.103 0.993 1.054
0.355 1.292 0.751 2.221
0.004 0.116
ortality in emergency department sepsis score, PCT procalcitonin, ALC absolute
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from Shubin and colleagues were collected at different
times after ICU admission and the patients had already
been subjected to standardized therapy in the ICU. The
median number of sampling times for patients with
sepsis were significantly longer than those of patients
with SIRS (21 vs 4), whereas our patient samples were
collected within 24 h of ED admission. Therefore, the
patients in the Shubin study may already have been in
the immunosuppression stage of sepsis, whereas our
patients were still in the early stages of sepsis. Add-
itionally, whether the levels of BTLA expression on
CD4+ T cells change over time remains unknown.
However, one study showed that the level of PD-1 ex-
pression on CD8+ T cells increased over time during
sepsis [21]. Therefore, it is possible that the level of
BTLA expression also varies and further studies are
needed to certify this.
Unlike other co-inhibitory receptors, our results sug-
gested that lower levels of BTLA expression on CD4+ T
cells during the early stage of sepsis may increase the
risk of pejorative outcome. Many studies on BTLA have
indicated similar results. Treatment with an agonistic
anti-BTLA antibody was found by Albring and col-
leagues to prevent graft-versus-host disease [22]. Oya
and colleagues found that BTLA inhibited lipopolysac-
charide (LPS)-induced endotoxic shock and that agonis-
tic anti-BTLA antibody had therapeutic potential for
endotoxic shock [23]. Collectively, these studies sug-
gested that high levels of BTLA expression may play a
protective role during the early stage of sepsis.
Although both proinflammatory and anti-inflammatory
processes begin promptly after the initiation of sepsis, in
general there is predominance of an initial hyperinflam-
matory phase [24]. The expression of inhibitory molecule
was upregulated to prevent the cytokine storm in the early
stage of the host response from inducing organ failure.
However, it was detrimental if the expression of inhibitory
molecule persisted during the stage of immunosuppres-
sion. The primary role of BTLA in CD4+ T cells is thought
to be suppressing proflammatory responses [17]. There-
fore, low BTLA expression during the first stage of sepsis
may result in an over-zealous proinflammatory response
which might be as detrimental as high expression at latter
stages. The study by Oya and colleagues found that BTLA
suppresses cytokine production in innate immune cells
and that BTLA-deficient mice are highly susceptible to
LPS-induced shock [23]. In contrast to other inhibitory
molecules, the changes in BTLA expression during the
early stage of sepsis may be more useful for evaluating the
prognosis of patients with sepsis. However, scarce data are
available on BTLA expression in patients with sepsis and
further studies are required for understanding the molecu-
lar mechanisms.In this study, BTLA expression on CD4+ T cells was a
reliable outcome predictor, similar to the MEDS score
and better than PCT. Of note, our results showed that
ALC was obviously decreased in patients with sepsis,
which is consistent with the study by Castelino and col-
leagues, who reported that lymphopenia (often at levels
of less than half of the reference value) in hospitalized
patients is most frequently caused by acute illness, not-
ably sepsis and trauma [25]. Similarly, Jahangiri and
colleagues reported that patients with sepsis had a sig-
nificant decrease in their ALC (53 % lower compared
with controls) [26]. It remains unclear if lymphocyte
apoptosis occurs at the onset of sepsis, so this observa-
tion should be explored in future studies.
It is important to distinguish between the functions
of BTLA in the innate and adaptive immune response.
The innate immune response is the host’s first line of
defense against infection and it is essential for the initi-
ation of adaptive immune response. Sun and colleagues
showed that BTLA-deficient mice exhibited signifi-
cantly higher bacterial clearance in the early innate im-
munity [27]. Shubin and colleagues demonstrated that
BTLA expression contributed to septic morbidity and
mortality in the early phase of immune response [28].
However, it has also been found that BTLA inhibits
LPS-induced endotoxic shock and proinflammatory
cytokine production [21]. BTLA also plays an import-
ant role in acquired immune responses. Oya and
colleagues showed that BTLA-deficiency mice are suscep-
tible to developing autoimmune hepatitis-like disease
[29]. Administration of agonistic anti-BTLA antibody
has been shown to prevent graft-versus-host disease
[22]. Our results showed that low levels of BTLA
expression may be a risk factor for septic mortality.
Additional studies examining the BTLA expression
during both the innate and adaptive immunity will be
required to fully understand the roles of BTLA in pa-
tients with sepsis.
Our study has several limitations. First, though it had
a relatively large sample size, it was a single-center
study and the findings need to be confirmed by a multi-
center study. Second, the dynamic changes in the levels
of BTLA expression on CD4+ T cells and the absolute
number for BTLA expression on CD4+ T cells remain
targets for future study. Third, our multivariate analysis
has been adjusted for several potential confounding
factors, but some risk factors, such as nutritional sta-
tus, could not be considered. Poor nutritional status
may be a major factor in the aggravation of sepsis, and
a previous study has shown that malnutrition has sev-
eral effects on host immunity [30]. Finally, this study
was only an observational study and further studies are
required to elaborate on the molecular mechanisms re-
sponsible for our findings.
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In conclusion, our study shows that the percentage of
BTLA+/CD4+ T cells was high in healthy volunteers.
Furthermore, a lower percentage of BTLA+/CD4+ T cells
during the early stage of sepsis is associated with the se-
verity of sepsis and the mortality of patients with sepsis.
Key messages
 The percentage of BTLA+/CD4+ T cells was high in
healthy volunteers
 A lower percentage of BTLA+/CD4+ T cells in the
early stage of sepsis is associated with the severity of
sepsis
 The percentage of BTLA+/CD4+T cells was lower in
non-survivors than in survivors, and similar results
were obtained when expressed as MFI
 The percentage of BTLA+/CD4+ T cells in the early
stage of sepsis is associated with 28-day mortality in
patients with sepsis, severe sepsis and septic shock
Abbreviations
ALC: absolute lymphocyte count; AUC: area under the receiver operating
characteristic curve; BTLA: B and T lymphocyte attenuator; CI: confidence
interval; ED: Emergency Department; FiO2: inspired oxygen fraction;
FITC: fluorescein isothiocyanate; FSC: forward scatter; LPS: lipolysaccharide;
MEDS: mortality in emergency department sepsis; MFI: mean of fluorescence
intensities; NPV: negative predictive value; OR: odds ratio; PaCO2: arterial
partial pressure of carbon dioxide; PCT: procalcitotin; PD-1: programmed
death receptor-1; PE: phycoerythrin; PPV: positive predictive value;
ROC: receiver operating characteristic; SIRS: systemic inflammatory response
syndrome; SSC: side scatter; WBC: white blood count.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
CSL conceived and designed the study, was involved in drafting the
manuscript and provided research funding. YYF collected data and critically
revised the manuscript. LXZ contributed to study design, collected data and
critically revised the manuscript. CCH collected data and critically revised the
manuscript. RS collected and analyzed data, performed statistical analysis,
drafted and critically revised the manuscript. All authors gave final approval
for manuscript publication and agree to be accountable for all aspects of
this work.
Authors’ information
C-SL is specialist of critical disease and the chief of the Emergency
Department of Beijing Chao-yang Hospital. RS, Y-YF, L-XZ, C-CH are graduate
students of Emergency Medicine who are conducting a study of sepsis.
Acknowledgements
The authors sincerely thank DR. Shuo Wang for his excellent assistance. The
study was conducted thanks to the helpful contributions of the ED staff and
Biochemistry Laboratory staff.
Received: 7 May 2015 Accepted: 11 August 2015
References
1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med.
1999;340:207–14.3. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885–91.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl
J Med. 2003;348:138–50.
5. Hotchkiss RS, Opal S. Immunotherapy for sepsis – a new approach against
an ancient foe. N Engl J Med. 2010;363:87–9.
6. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al.
Immunosuppression in patients who die of sepsis and multiple organ
failure. JAMA. 2011;306:2594–605.
7. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is
a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat
Immunol. 2003;4:670–9.
8. Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T
lymphocyte attenuator exhibits structural and expression polymorphisms
and is highly induced in anergic CD4+ T cells. J Immunol. 2005;174:3377–85.
9. Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM. B and T
lymphocyte attenuator regulates T cell survival in the lung. J Immunol.
2008;181:2973–9.
10. Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A. B and T
lymphocyte attenuator expression on CD4+ T-cells associates with sepsis
and subsequent infections in ICU patients. Crit Care. 2013;17:R276.
11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.
International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS
International sepsis definitions conference. Intensive Care Med. 2003;29:530–8.
12. Calandra T, Cohen J. The international sepsis forum consensus conference on
definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538–48.
13. Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW. Mortality in
emergency department sepsis (MEDS) scores: a prospectively derived and
validated clinical prediction rule. Crit Care Med. 2003;31:670–5.
14. Munford RS, Pugin J. Normal responses to injury prevent systemic
inflammation and can be immunosuppressive. Am J Respir Crit Care Med.
2001;163:316–21.
15. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and
inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.
16. Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, et al. Cutting
edge: a critical role of B and T lymphocyte attenuator in peripheral T cell
tolerance induction. J Immunol. 2009;182:4516–20.
17. Bandyopadhyay G, De A, Laudanski K, Li F, Lentz C, Bankey P, et al. Negative
signaling contributes to T-cell anergy in trauma patients. Crit Care Med.
2007;35:794–801.
18. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte
attenuator in sustaining cell survival during chronic allostimulation.
J Immunol. 2007;178:6073–82.
19. Zhang Z, Xu X, Lu J, Zhang S, Gu L, Fu J, et al. B and T Lymphocyte
Attenuator Down-regulation by HIV-1 Depends on Type I Interferon and
Contributes to T-Cell Hyperactivation. J Infect Dis. 2011;203:1668–78.
20. Partyka A, Woszczyk D, Strzała T, Szczepańska A, Tomkiewicz A, Frydecka I,
et al. Gene polymorphisms of novel immunotolerant molecule btla:
distribution of alleles, genotypes and haplotypes in Polish Caucasian
population. Arch Immunol Ther Exp (Warsz). 2015;63:73–8.
21. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al.
Targeting the programmed cell death 1: programmed cell death ligand 1
pathway reverses T cell exhaustion in patients with sepsis. Crit Care.
2014;18:R3.
22. Albring JC, Sandau MM, Rapaport AS, Edelson BT, Satpathy A, Mashayekhi
M, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-
versus-host disease without global immunosuppression. J Exp Med.
2010;207:2551–9.
23. Kobayashi Y, Iwata A, Suzuki K, Suto A, Kawashima S, Saito Y, et al. B and T
lymphocyte attenuator inhibits LPS-induced endotoxic shock by
suppressing Toll-like receptor 4 signaling in innate immune cells. Proc Nat
Acad Sci. 2013;110:5121–6.
24. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. Lancet
Infect Dis. 2013;13:260–8.
25. Castelino DJ, McNair P, Kay TW. Lymphocytopenia in a hospital population -
what does it signify? Aust NJ Med. 1997;27:170–4.
26. Jahangiri M, Wyllie JH. Peripheral blood lymphopenia: In gangrenous
appendicitis. BMJ. 1990;301:215.
27. Sun Y, Brown NK, Ruddy MJ, Miller ML, Lee Y, Wang Y, et al. B and T
lymphocyte attenuator tempers early infection immunity. J Immunol.
2009;183:1946–51.
Shao et al. Critical Care  (2015) 19:308 Page 9 of 928. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A. BTLA
expression contributes to septic morbidity and mortality by inducing innate
inflammatory cell dysfunction. J Leukoc Biol. 2012;92:593–603.
29. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, et al. Development
of autoimmune hepatitis-like disease and production of autoantibodies to
nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis
Rheum. 2008;58:2498–510.
30. Hughes SM, Amadi B, Mwiya M, Nkamba H, Tomkins A, Goldblatt D.
Dendritic cell anergy results from endotoxemia in severe malnutrition.
J Immunol. 2009;183:2818–26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
